The genomics of heart failure: design and rationale of the HERMES consortium
Author
Lumbers, R ThomasShah, Sonia
Lin, Honghuang
Czuba, Tomasz
Henry, Albert
Swerdlow, Daniel I
Mälarstig, Anders
Andersson, Charlotte
Verweij, Niek
Holmes, Michael V
Ärnlöv, Johan
Svensson, Per
Hemingway, Harry
Sallah, Neneh
Almgren, Peter
Aragam, Krishna G
Asselin, Geraldine
Backman, Joshua D
Biggs, Mary L
Bloom, Heather L
Boersma, Eric
Brandimarto, Jeffrey
Brown, Michael R
Brunner-La Rocca, Hans-Peter
Carey, David J
Chaffin, Mark D
Chasman, Daniel I
Chazara, Olympe
Chen, Xing
Chen, Xu
Chung, Jonathan H
Chutkow, William
Cleland, John G F
Cook, James P
de Denus, Simon
Dehghan, Abbas
Delgado, Graciela E
Denaxas, Spiros
Doney, Alexander S
Dörr, Marcus
Dudley, Samuel C
Engström, Gunnar
Esko, Tõnu
Fatemifar, Ghazaleh
Felix, Stephan B
Finan, Chris
Ford, Ian
Fougerousse, Francoise
Fouodjio, René
Ghanbari, Mohsen
Ghasemi, Sahar
Giedraitis, Vilmantas
Giulianini, Franco
Gottdiener, John S
Gross, Stefan
Guðbjartsson, Daníel F
Gui, Hongsheng
Gutmann, Rebecca
Haggerty, Christopher M
van der Harst, Pim
Hedman, Åsa K
Helgadottir, Anna
Hillege, Hans
Hyde, Craig L
Jacob, Jaison
Jukema, J Wouter
Kamanu, Frederick
Kardys, Isabella
Kavousi, Maryam
Khaw, Kay-Tee
Kleber, Marcus E
Køber, Lars
Koekemoer, Andrea
Kraus, Bill
Kuchenbaecker, Karoline
Langenberg, Claudia
Lind, Lars
Lindgren, Cecilia M
London, Barry
Lotta, Luca A
Lovering, Ruth C
Luan, Jian'an
Magnusson, Patrik
Mahajan, Anubha
Mann, Douglas
Margulies, Kenneth B
Marston, Nicholas A
März, Winfried
McMurray, John J V
Melander, Olle
Melloni, Giorgio
Mordi, Ify R
Morley, Michael P
Morris, Andrew D
Morris, Andrew P
Morrison, Alanna C
Nagle, Michael W
Nelson, Christopher P
Newton-Cheh, Christopher
Niessner, Alexander
Niiranen, Teemu
Nowak, Christoph
O'Donoghue, Michelle L
Owens, Anjali T
Palmer, Colin N A
Paré, Guillaume
Perola, Markus
Perreault, Louis-Philippe Lemieux
Portilla-Fernandez, Eliana
Psaty, Bruce M
Rice, Kenneth M
Ridker, Paul M
Romaine, Simon P R
Roselli, Carolina
Rotter, Jerome I
Ruff, Christian T
Sabatine, Marc S
Salo, Perttu
Salomaa, Veikko
van Setten, Jessica
Shalaby, Alaa A
Smelser, Diane T
Smith, Nicholas L
Stefansson, Kari
Stender, Steen
Stott, David J
Sveinbjörnsson, Garðar
Tammesoo, Mari-Liis
Tardif, Jean-Claude
Taylor, Kent D
Teder-Laving, Maris
Teumer, Alexander
Thorgeirsson, Guðmundur
Thorsteinsdottir, Unnur
Torp-Pedersen, Christian
Trompet, Stella
Tuckwell, Danny
Tyl, Benoit
Uitterlinden, Andre G
Vaura, Felix
Veluchamy, Abirami
Visscher, Peter M
Völker, Uwe
Voors, Adriaan A
Wang, Xiaosong
Wareham, Nicholas J
Weeke, Peter E
Weiss, Raul
White, Harvey D
Wiggins, Kerri L
Xing, Heming
Yang, Jian
Yang, Yifan
Yerges-Armstrong, Laura M
Yu, Bing
Zannad, Faiez
Zhao, Faye
Wilk, Jemma B
Holm, Hilma
Sattar, Naveed
Lubitz, Steven A
Lanfear, David E
Shah, Svati
Dunn, Michael E
Wells, Quinn S
Asselbergs, Folkert W
Hingorani, Aroon D
Dubé, Marie-Pierre
Samani, Nilesh J
Lang, Chim C
Cappola, Thomas P
Ellinor, Patrick T
Vasan, Ramachandran S
Smith, J Gustav
Date
2021-09-03Journal
ESC Heart FailurePublisher
Wiley-BlackwellType
Article
Metadata
Show full item recordAbstract
Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.Rights/Terms
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.Identifier to cite or link to this item
http://hdl.handle.net/10713/16610ae974a485f413a2113503eed53cd6c53
10.1002/ehf2.13517
Scopus Count
Collections
Related articles
- Strategies to design and analyze targeted sequencing data: cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study.
- Authors: Lin H, Wang M, Brody JA, Bis JC, Dupuis J, Lumley T, McKnight B, Rice KM, Sitlani CM, Reid JG, Bressler J, Liu X, Davis BC, Johnson AD, O'Donnell CJ, Kovar CL, Dinh H, Wu Y, Newsham I, Chen H, Broka A, DeStefano AL, Gupta M, Lunetta KL, Liu CT, White CC, Xing C, Zhou Y, Benjamin EJ, Schnabel RB, Heckbert SR, Psaty BM, Muzny DM, Cupples LA, Morrison AC, Boerwinkle E
- Issue date: 2014 Jun
- ADAM19 and HTR4 variants and pulmonary function: Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study.
- Authors: London SJ, Gao W, Gharib SA, Hancock DB, Wilk JB, House JS, Gibbs RA, Muzny DM, Lumley T, Franceschini N, North KE, Psaty BM, Kovar CL, Coresh J, Zhou Y, Heckbert SR, Brody JA, Morrison AC, Dupuis J
- Issue date: 2014 Jun
- Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated With Cardiac Morphogenesis and Heart Failure Development.
- Authors: Aung N, Vargas JD, Yang C, Cabrera CP, Warren HR, Fung K, Tzanis E, Barnes MR, Rotter JI, Taylor KD, Manichaikul AW, Lima JAC, Bluemke DA, Piechnik SK, Neubauer S, Munroe PB, Petersen SE
- Issue date: 2019 Oct 15
- Advances in the Genetics and Genomics of Heart Failure.
- Authors: Reza N, Owens AT
- Issue date: 2020 Sep 10
- Genetic and ElectroNic medIcal records to predict oUtcomeS in Heart Failure patients (GENIUS-HF) - design and rationale.
- Authors: Gioli-Pereira L, Bernardez-Pereira S, Goulart Marcondes-Braga F, Rocha Spina JM, Muniz Miranda da Silva R, Evangelista Ferreira N, Bacal F, Fernandes F, Mansur AJ, Krieger JE, Costa Pereira A
- Issue date: 2014 Mar 4
Related items
Showing items related by title, author, creator and subject.
-
Les progrès dans la réalisation de la classification quantitative de la psychopathologieKrueger, Robert F; Kotov, Roman; Watson, David; Forbes, Miriam K; Eaton, Nicholas R; Ruggero, Camilo J; Simms, Leonard J; Widiger, Thomas A; Achenbach, Thomas M; Bach, Bo; et al. (Elsevier Ltd., 2021-01-08)Shortcomings of approaches to classifying psychopathology based on expert consensus have given rise to contemporary efforts to classify psychopathology quantitatively. In this paper, we review progress in achieving a quantitative and empirical classification of psychopathology. A substantial empirical literature indicates that psychopathology is generally more dimensional than categorical. When the discreteness versus continuity of psychopathology is treated as a research question, as opposed to being decided as a matter of tradition, the evidence clearly supports the hypothesis of continuity. In addition, a related body of literature shows how psychopathology dimensions can be arranged in a hierarchy, ranging from very broad "spectrum level" dimensions, to specific and narrow clusters of symptoms. In this way, a quantitative approach solves the "problem of comorbidity" by explicitly modeling patterns of co-occurrence among signs and symptoms within a detailed and variegated hierarchy of dimensional concepts with direct clinical utility. Indeed, extensive evidence pertaining to the dimensional and hierarchical structure of psychopathology has led to the formation of the Hierarchical Taxonomy of Psychopathology (HiTOP) Consortium. This is a group of 70 investigators working together to study empirical classification of psychopathology. In this paper, we describe the aims and current foci of the HiTOP Consortium. These aims pertain to continued research on the empirical organization of psychopathology; the connection between personality and psychopathology; the utility of empirically based psychopathology constructs in both research and the clinic; and the development of novel and comprehensive models and corresponding assessment instruments for psychopathology constructs derived from an empirical approach.
-
Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemicNguyen, Thanh N; Haussen, Diogo C; Qureshi, Muhammad M; Yamagami, Hiroshi; Fujinaka, Toshiyuki; Mansour, Ossama Y; Abdalkader, Mohamad; Frankel, Michael; Qiu, Zhongming; Taylor, Allan; et al. (BMJ Publishing Group, 2021-03-26)Background: During the COVID-19 pandemic, decreased volumes of stroke admissions and mechanical thrombectomy were reported. The study's objective was to examine whether subarachnoid haemorrhage (SAH) hospitalisations and ruptured aneurysm coiling interventions demonstrated similar declines. Methods: We conducted a cross-sectional, retrospective, observational study across 6 continents, 37 countries and 140 comprehensive stroke centres. Patients with the diagnosis of SAH, aneurysmal SAH, ruptured aneurysm coiling interventions and COVID-19 were identified by prospective aneurysm databases or by International Classification of Diseases, 10th Revision, codes. The 3-month cumulative volume, monthly volumes for SAH hospitalisations and ruptured aneurysm coiling procedures were compared for the period before (1 year and immediately before) and during the pandemic, defined as 1 March-31 May 2020. The prior 1-year control period (1 March-31 May 2019) was obtained to account for seasonal variation. Findings: There was a significant decline in SAH hospitalisations, with 2044 admissions in the 3 months immediately before and 1585 admissions during the pandemic, representing a relative decline of 22.5% (95% CI -24.3% to -20.7%, p<0.0001). Embolisation of ruptured aneurysms declined with 1170-1035 procedures, respectively, representing an 11.5% (95%CI -13.5% to -9.8%, p=0.002) relative drop. Subgroup analysis was noted for aneurysmal SAH hospitalisation decline from 834 to 626 hospitalisations, a 24.9% relative decline (95% CI -28.0% to -22.1%, p<0.0001). A relative increase in ruptured aneurysm coiling was noted in low coiling volume hospitals of 41.1% (95% CI 32.3% to 50.6%, p=0.008) despite a decrease in SAH admissions in this tertile. Interpretation: There was a relative decrease in the volume of SAH hospitalisations, aneurysmal SAH hospitalisations and ruptured aneurysm embolisations during the COVID-19 pandemic. These findings in SAH are consistent with a decrease in other emergencies, such as stroke and myocardial infarction.
-
Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals.Winkler, Thomas W; Rasheed, Humaira; Teumer, Alexander; Gorski, Mathias; Rowan, Bryce X; Stanzick, Kira J; Thomas, Laurent F; Tin, Adrienne; Hoppmann, Anselm; Chu, Audrey Y; et al. (Springer Nature, 2022-06-13)Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (nDM = 178,691, nnoDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM.